Sanara MedTech (SMTI) AI Stock Analysis

• Market Cap: $256.06M
• Dividend Yield: N/A
• Average Volume (3M): 31.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: 34.65%
• EPS Growth: -128.56%
• Country: US
• Employees: 141
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.41
• Shares Outstanding: 8,887,853
• 10 Day Avg. Volume: 35,102
• 30 Day Avg. Volume: 31,420
• PEG Ratio: -22.23
• Price to Book (P/B): 8.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -57.09
• Enterprise Value/Market Cap: 1.37
• Enterprise Value/Revenue: 1.07
• Enterprise Value/Gross Profit: 4.29
• Enterprise Value/Ebitda: -33.58
• 1Y Price Target: $49.00
• Price Target Upside: 70.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 50 Neutral
• Price Target: $32.00 ▲(11.07%Upside)

Sanara MedTech's overall stock score reflects its strong revenue growth and product sales expansion, which are significant positives. However, these are balanced by ongoing concerns in profitability, cash flow management, and increased leverage. The technical analysis suggests neutral market momentum, and the valuation is challenged by negative earnings. The earnings call highlights both growth opportunities and financial challenges, shaping a mixed overall outlook.

Positive Factors

Financial Performance

Analyst reiterates Buy rating while raising the 12-month price target to $53 per share.

Revenue Growth

Revenue grew 26%, driven primarily by increased demand for CellerateRX Surgical Activated Collagen due to expansion into additional medical facilities.

Strategic Partnerships

Sanara entered an exclusive license and distribution agreement with Biomimetic Innovations Ltd for a breakthrough device, enriching Sanara’s existing surgical product offerings.

Negative Factors

Financial Risks

Risks include lower-than-projected revenue growth, inability to secure additional customers, and potential dilution risk.

Net Loss

The company reported a net loss of $9.7M for FY2024, although it was less than the estimated loss.

Revenue Challenges

Approximately $1.8M of BIASURGE sales in 4Q24 was attributable to a unique situation (Hurricane Helene), with sales expected to normalize.

Sanara MedTech Business Overview & Revenue Model

Company Description

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

How the Company Makes Money

Sanara MedTech makes money through the sale of its advanced wound care products to hospitals, clinics, and other healthcare providers. The company's revenue model is primarily product-based, with income generated from the direct sale of its proprietary wound care solutions. Key revenue streams include its line of wound healing and infection prevention products. Sanara MedTech may also engage in partnerships with other healthcare entities to expand its market reach and enhance its product distribution. Collaborations with medical professionals and participation in clinical studies can also contribute to the company's earnings by validating the effectiveness of its products and facilitating broader adoption.

Sanara MedTech Financial Statement Overview

Summary

Sanara MedTech is experiencing robust revenue growth, yet it struggles with profitability and cash flow management. The company's high gross margins are overshadowed by negative net income and cash flows. Increasing leverage and reliance on financing activities highlight potential risks. While the company demonstrates growth potential, it must address operational inefficiencies to achieve sustainable profitability.

Income Statement

Sanara MedTech has shown significant revenue growth over the years, with a 40% increase from 2023 to TTM (Trailing-Twelve-Months). However, profitability remains a concern as indicated by negative net profit margins and EBIT margins throughout the periods. The gross profit margin is strong at approximately 89% for TTM, but consistent net losses and negative EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio has increased over time, reaching 1.22 in TTM, indicating higher leverage. The equity ratio has decreased, reflecting a higher proportion of debt financing. Despite these challenges, Sanara MedTech maintains a reasonable level of stockholders' equity relative to assets, and the return on equity has been negative due to persistent net losses.

Cash Flow

Sanara MedTech faces challenges with its cash flows, indicated by negative free cash flow and operating cash flow in TTM. The company has managed to raise capital through financing activities, which provides a temporary cushion. However, the free cash flow to net income ratio remains negative, pointing to ongoing cash burn relative to net losses.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
91.57M	86.67M	64.99M	45.84M	24.14M	15.59M
	Gross Profit
81.88M	78.53M	57.14M	39.48M	21.83M	13.97M
	EBIT
-6.14M	-6.72M	-4.22M	-12.23M	-7.38M	-5.00M
	EBITDA
-1.27M	-1.86M	-289.10K	-11.85M	-7.22M	-4.02M
	Net Income Common Stockholders
-11.43M	-9.66M	-4.30M	-8.09M	-7.31M	-4.38M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
20.69M	15.88M	5.15M	8.96M	18.65M	455.37K
	Total Assets
59.54M	88.09M	73.87M	61.04M	36.40M	9.83M
	Total Debt
44.72M	32.29M	11.79M	819.22K	425.44K	481.38K
	Net Debt
24.03M	16.41M	6.64M	-8.14M	-18.23M	26.02K
	Total Liabilities
46.43M	49.18M	29.28M	19.32M	6.24M	3.99M
	Stockholders Equity
36.67M	39.40M	44.83M	41.83M	30.64M	6.15M
Cash Flow		Free Cash Flow
-2.31M	-229.63K	-3.51M	-6.30M	-5.56M	-5.68M
	Operating Cash Flow
-428.30K	-23.78K	-3.25M	-5.55M	-4.81M	-4.03M
	Investing Cash Flow
-11.73M	-6.61M	-10.21M	-3.51M	-5.28M	-2.74M
	Financing Cash Flow
30.01M	17.37M	9.64M	-627.35K	28.30M	622.33K

Sanara MedTech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 28.81
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMTI, the sentiment is Negative. The current price of 28.81 is below the 20-day moving average (MA) of 29.77, below the 50-day MA of 30.35, and below the 200-day MA of 32.87, indicating a bearish trend. The MACD of -0.63 indicates Positive momentum. The RSI at 41.50 is Neutral, neither overbought nor oversold. The STOCH value of 34.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SMTI.

Sanara MedTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	67 Neutral	$179.17M	14.60	10.59%	2.21%	-19.92%	―
PDEX	63 Neutral	$129.01M	14.14	28.29%	―	29.65%	131.78%
STXS	60 Neutral	$181.46M	―	-179.82%	―	1.50%	-20.00%
OSUR	57 Neutral	$220.66M	25.27	-7.77%	―	-46.95%	-237.44%
ANGO	56 Neutral	$432.87M	―	-20.46%	―	-12.56%	78.70%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
SMTI	50 Neutral	$256.06M	―	-28.58%	―	34.65%	-128.56%

Sanara MedTech Corporate Events

Sanara MedTech Updates Investor Presentation Online

On May 22, 2025, Sanara MedTech Inc. held its Annual Meeting of Shareholders, where a total of 6,781,075 shares were represented. During the meeting, the election of eight directors to the Board and the ratification of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were approved by the shareholders. Additionally, on May 27, 2025, the company updated its investor presentation on its website, emphasizing the importance of monitoring their Investor Relations section for material information.

The most recent analyst rating on (SMTI) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Sanara MedTech stock, see the SMTI Stock Forecast page.

Sanara MedTech’s CAO Michael McNeil Announces Retirement

On May 19, 2025, Michael D. McNeil announced his retirement from his roles as Chief Accounting Officer and Chief Administrative Officer at Sanara MedTech Inc., effective August 19, 2025. The company is in discussions with McNeil for a consulting role to aid in the transition. Elizabeth B. Taylor, the current Chief Financial Officer, will take over McNeil’s responsibilities as the principal accounting officer.

The most recent analyst rating on (SMTI) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Sanara MedTech stock, see the SMTI Stock Forecast page.

Sanara MedTech to Present at Investor Showcase

Sanara MedTech Inc. announced that it will be presenting an investor presentation at the Planet MicroCap Showcase in Las Vegas on April 23, 2025. The presentation, which is part of the company’s ongoing communication with investors and analysts, is intended to provide summary information in the context of the company’s SEC filings and public announcements.